Format

Send to

Choose Destination
Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):1003-1018. doi: 10.1016/j.bbadis.2018.07.029. Epub 2018 Aug 1.

In vitro and in vivo translational models for rare liver diseases.

Author information

1
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
2
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA. Electronic address: elizabeth.ottinger@nih.gov.

Abstract

A challenge in developing effective treatments is the modeling of the human disease using in vitro and in vivo systems. Animal models have played a critical role in the understanding of disease pathophysiology, target validation, and evaluation of novel therapeutic agents. However, as the success rate from entry into clinical testing to drug approval remains low, it is critical to have high quality and well-validated models reflective of the disease condition. Additional experimental models are being developed based on functional in vitro 3D tissue models such as organoids and 3D bioprinted tissues. Because these 3D tissue models mimic closer the architecture, cell composition and physiology of native tissues, they are now being used as screening platforms in drug discovery and development and for tissue transplant in regenerative medicine. Here we review the current state-of-art of in vitro and in vivo translational models for the development of therapies for rare diseases of the liver.

KEYWORDS:

3D tissue; Animal model; Liver; Organoids; Rare disease; Translational model

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center